Search Results

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.

• Authors : Schmieder, G.J.; Draelos, Z.D.; Pariser, D.M.

Subjects: KINASE inhibitors; PSORIASIS; PSORIASIS treatment

• Source: British Journal of Dermatology; Jul2018, Vol. 179 Issue 1, p54-62, 9p

Record details

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

• Authors : Vermeire, Séverine; Schreiber, Stefan; Petryka, Robert

Subjects: JANUS kinases; INFLAMMATORY bowel disease treatment; CROHN'S disease

• Source: Lancet. 1/21/2017, Vol. 389 Issue 10066, p266-275. 10p. 1 Diagram, 3 Charts, 2 Graphs.

Record details

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.

• Authors : Bissonnette, Robert; Luchi, Monica; Fidelus-Gort, Rosanne

Subjects: PSORIASIS; INFLAMMATION treatment; CYTOKINES

• Source: Journal of Dermatological Treatment; Aug2016, Vol. 27 Issue 4, p332-338, 7p

Record details

Agricola

Record details

Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.

• Authors : Oritani, Kenji¹; Ohishi, Kohshi²; Okamoto, Shinichiro³

Subjects: *MYELOFIBROSIS; *JANUS kinases; *PATIENTS

• Source: Current Medical Research & Opinion. Mar2018, Vol. 34 Issue 3, p531-537. 7p.

Record details

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.

• Authors : Trueman, Sheryl; Mohamed, Mohamed‐Eslam F.; Feng, Tian

Subjects: LIVER physiology; CLASSIFICATION; CONFIDENCE intervals

• Source: Journal of Clinical Pharmacology; Sep2019, Vol. 59 Issue 9, p1188-1194, 7p

Record details

DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.

• Authors : van Vollenhoven, R F¹; Layton, M²; Kahl, L³

Subjects: *JANUS kinases; *DRESS syndrome; *SYSTEMIC lupus erythematosus

• Source: Lupus. May2015, Vol. 24 Issue 6, p648-649. 2p.

Record details

Thromboembolism and Janus Kinase Inhibitors.

• Authors : Ibrahim, Fowzia¹; Scott, David L.¹

Subjects: *JANUS kinases; *THROMBOEMBOLISM; *DRUGS

• Source: Drug Safety. Sep2020, Vol. 43 Issue 9, p831-833. 3p.

Record details

JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia.

• Authors : de Bock, Charles E.^1,2 (AUTHOR); Cools, Jan^1,2 (AUTHOR)

Subjects: *LYMPHOBLASTIC leukemia; *JANUS kinases; *GENETIC vectors

• Source: Molecular & Cellular Oncology. May2018, Vol. 5 Issue 3, p1-N.PAG. 3p.

Record details

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

• Authors : Taylor, Peter C.; Keystone, Edward C.; van der Heijde, Désirée

Subjects: DRUG efficacy; JANUS kinases; ADALIMUMAB

• Source: New England Journal of Medicine. 2/16/2017, Vol. 376 Issue 7, p652-662. 11p.

Record details